Additionally, the elevated levels of U-II and TGF-β in smokers, though lower than in COPD patients, suggest that these profibrotic molecules may be activated early in the disease process, even before the onset of clinically significant airflow obstruction. Here, TGFB1 is linked to chronic obstructive pulmonary disease.